Clinical efficacy of miglitol in type 2 Japanese diabetics with diet alone - Phase II dose response study

Japanese Pharmacology and Therapeutics

Volumn 33, Issue 11, 2005, Pages 1099-1111

  Goto, Tohoku ^a  

^a Tohoku Kouseinenkin Hospital   (Japan)

Author keywords

Alpha glucosidase inhibitor; Dose response study; Glycaemic control; Postprandial hyperglycaemia

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; GLUCOSE; HEMOGLOBIN A1C; MIGLITOL; PLACEBO;

ABDOMINAL DISTENSION; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIET THERAPY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG STRUCTURE; DRUG TOLERABILITY; FEMALE; FLATULENCE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; JAPAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

EID: 32844470112     PISSN: 03863603     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329 (14): 977-86.
2. Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000; 23 Suppl 2: B21-9.
3. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352 (9131): 837-53.
4. Hanefeld M, Fischer S, Julius U, Schulze J, Schwanebeck U, Schmechel H, et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996; 39 (12): 1577-83.
5. Donahue RP, Abbott RD, Reed DM, Yano K. Postchallenge glucose concentration and coronary heart disease in men of Japanese ancestry: Honolulu Heart Program. Diabetes 1987; 36 (6): 689-92.
6. Rodriguez BL, Lau N, Burchfiel CM, Abbott RD, Sharp DS, Yano K, et al. Glucose intolerance and 23-year risk of coronary heart disease and total mortality: the Honolulu Heart Program. Diabetes Care 1999; 22 (8): 1262-5.
7. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group on behalf of the European Diabetes Epidemiology Group. Lancet 1999; 354 (9179): 617-21.
8. Fujishima M, Kiyohara Y, Kato I, Ohmura T, Iwamoto H, Nakayama K, et al. Diabetes and cardiovascular disease in a prospective population survey in Japan: The Hisayama Study. Diabetes 1996; 45 Suppl 3: S14-6.
9. Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose: The Funagata Diabetes Study. Diabetes Care 1999; 22 (6): 920-4.
10. STOP-NIDDM Trial Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002; 359 (9323): 2072-7.
11. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003; 290 (4): 486-94.
12. Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J 2004; 25 (1): 10-6.
13. Junge B, Matzke M, Stolftefuss J. Chemistry and structure-activity relationships of glucosidase inhibitors. In: Kuhlman J, Puls W, editors. Handbook of experimental pharmacology, vol 119. Berlin, Heidelberg, New York: Springer; 1996. p. 411-82.
14. Drent ML, Tollefsen AT, van Heusden FH, Hoenderdos EB, Jonker JJ, van der Veen EA. Dose-dependent efficacy of miglitol, an alpha-glucosidase inhibitor, in type 2 diabetic patients on diet alone: results of a 24-week double-blind placebo-controlled study. Diabetes Nutr Metab 2002; 15 (3): 152-9.
15. Osonoi T, Onuma T, Kawamori R. Effects of miglitol on plasma glucose, serum insulin and lipid metabolism in post-prandial state of Type 2 diabetics. Diabetes Metab 2003; 29: 4S263.
16. de Luis Roman DA, del Pozo Garcia E, Aller R, Romero Bobillo E, Conde Valentin R. Usefulness of miglitol in patients with diabetes mellitus type 2 and insufficient control of the blood glucose. Rev Clin Esp 2004; 204 (1): 32-4. Spanish.
17. Vichayanrat A, Ploybutr S, Tunlakit M, Watanakejorn P. Efficacy and safety of voglibose in comparison with acarbose in type 2 diabetic patients. Diabetes Res Clin Pract 2002; 55 (2): 99-103.
18. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 2002; 287 (3): 360-72.
19. Olefsky JM. Lilly lecture 1980. Insulin resistance and insulin action. An in vitro and in vivo perspective. Diabetes 1981; 30 (2): 148-62.
20. (Flier JS. In: Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL, editors. Harrison's principles of internal medicine. 15th ed. New York City. The McGraw-Hill Companies. 2001.)